This review has shown that blood-based p-tau biomarkers, particularly p-tau217, perform similarly to CSF and PET-based biomarkers, making them attractive for the early detection of AD. These findings suggest that blood-based p-tau biomarkers could serve as less invasive and more accessible alternatives to CSF and PET imaging for the early detection and diagnosis of AD. This evidence concerns the gene MAPT and Alzheimer disease.